Endologix Appoints Charles Love Vice President of Clinical Affairs

        Print
| Source: Endologix

IRVINE, Calif., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Charles Love to the position Vice President of Clinical Affairs. Mr. Love will be responsible for overseeing all Endologix U.S. and international clinical trials and will report to John McDermott, President and Chief Executive Officer. Janet Fauls, previously Vice President of Regulatory and Clinical Affairs, will maintain responsibility for overseeing Regulatory Affairs as the Company prepares for multiple upcoming potential regulatory milestones for its product pipeline.

Mr. McDermott, said, "Charles Love has more than twenty years of experience with medical devices in product development, regulatory strategy and clinical trial design. His extensive experience will be a valuable asset as we continue to advance our new product pipeline, including the U.S. clinical trials for the Ventana™ Fenestrated System and the Nellix® EndoVascular Aneurysm Sealing System. We look forward to Mr. Love joining our management team as we continue to expand our product portfolio and gain share in the AAA market."

Prior to joining Endologix, Mr. Love served as Vice President of Clinical and Regulatory Compliance at CircuLite, Inc., a privately held medical device company developing disruptive solutions for the treatment of chronic heart failure. He has also served as a consultant and held management level Clinical Affairs, Regulatory and Strategic Development positions for a variety of medical device companies, including Medtronic, CoreValve, nContact Surgical, Inc., Ventracor Limited, and Converge Medical, Inc. His experience also includes senior management positions at Ramus Medical Technologies and Autogenics. He serves on the Board of Directors for Loma Vista Medical and is on the Technical Advisory Board for Dexteritie Surgical.

Mr. Love received a B.A. in Biology from Westmont College. He also completed undergraduate work in Engineering at Gonzaga University and completed management programs at the University of California and Stanford University.

The Nellix® EndoVascular Aneurysm Sealing System is not approved in the United States for either investigational use or commercial sale. The Ventana™ Fenestrated System is an investigational device in the United States and internationally.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements relating to the Company's product pipeline, regulatory milestones and market share, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including delays in, product research and development efforts, regulatory submissions and approvals and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020